REGISTERED NUMBER: 06612614 (England and Wales)

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

STANDARD BIOTOOLS UK LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

H A Kim

M T Botella

SECRETARY:

Bird & Bird Company Secretaries Limited

REGISTERED OFFICE:

12 New Fetter Lane

London

United Kingdom

EC4A 1JP

REGISTERED NUMBER:

06612614 (England and Wales)

AUDITORS:

Oury Clark Chartered Accountants

Statutory Auditors

Herschel House

58 Herschel Street

Slough

Berkshire

SL1 1PG

CURRENT ASSETS

Debtors

4

3,773,829

2,228,145

Cash at bank

419,417

439,017

4,193,246

2,667,162

CREDITORS

Amounts falling due within one year

5

3,519,159

1,965,533

NET CURRENT ASSETS

674,087

701,629

TOTAL ASSETS LESS CURRENT LIABILITIES

674,087

701,629

CREDITORS

Amounts falling due after more than one year

6

53,212

167,188

NET ASSETS

620,875

534,441

CAPITAL AND RESERVES

Called up share capital

8

1,000

1,000

Capital contribution reserve

9

77,716

16,447

Retained earnings

9

542,159

516,994

SHAREHOLDERS' FUNDS

620,875

534,441

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 26 September 2025 and were signed on its behalf by:

H A Kim - Director

1.	STATUTORY INFORMATION

Standard BioTools UK Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on a going concern basis as Standard BioTools Inc., the ultimate Parent Company, will continue to support the Company as required for a period in excess of 12 months and 1 day from the signing of the audit report.

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Critical accounting judgements and key sources of estimation uncertainty

With regard to the accounting policies adopted by the company, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily available from other sources. Such estimates are based on historical experience and other relevant factors and may differ from actual results. All estimates, and associated underlying assumptions, are reviewed on an ongoing basis.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from the sale of products is recognised when the risks and rewards of ownership have been transferred.

Revenue from services is recognised once all the obligations have been fulfilled under the contract upon delivery.

Financial instruments

Basic financial instruments as covered by Section 11 of FRS 102 (Section 1A) are measured at amortised cost. The company does not have any Other Financial Instruments as covered by Section 12 of FRS 102 (Section 1A).

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Share-based payments

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services.

The cost of equity-settled transactions is measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the weighted average expected volatility, weighted average expected return, weighted average risk-free interest rate and dividend yield. No account is taken of any other vesting conditions.

The fair value of RSUs is determined by the share price at the date of transaction.

The cost of equity-settled transactions is recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods

The share based payment expense is recognised on a reasonable allocation of the group expense.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 27 (2023 - 20 ) .

4.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

£

Trade debtors

213,458

633,862

Amounts owed by group undertakings

3,506,058

1,508,327

Other debtors

54,313

85,956

3,773,829

2,228,145

5.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.24

31.12.23

£

£

Trade creditors

35,884

34,960

Amounts owed to group undertakings

2,181,843

557,372

Taxation and social security

25,129

27,245

Other creditors & accruals

1,276,303

1,345,956

3,519,159

1,965,533

6.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

31.12.24

31.12.23

£

£

Other creditors

53,212

167,188

7.	LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:

31.12.24

31.12.23

£

£

Within one year

24,252

43,062

Between one and five years

23,831

9,153

48,083

52,215

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.12.24

31.12.23

value:

£

£

1,000

Ordinary

£1

1,000

1,000

9.

RESERVES

Capital

Retained

contribution

earnings

reserve

Totals

£

£

£

At 1 January 2024

516,994

16,447

533,441

Deficit for the year

(23,591

)

(23,591

)

Share based payment charge

-

110,025

110,025

Transfer on exercised

securities

48,756

(48,756

)

-

At 31 December 2024

542,159

77,716

619,875

10.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Hayden Sym (Senior Statutory Auditor)

for and on behalf of Oury Clark Chartered Accountants

We would like to draw your attention to the following statement contained within our audit report as included within the full financial statements:-

"Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed."

11.	CONTINGENT LIABILITIES

HMRC is currently undertaking a VAT inspection of the company. One error has been identified to date, resulting in a VAT liability of £24,376. HMRC has requested further information and expanded the scope of their review, but no additional errors have been identified in the information reviewed to date. As the inspection remains ongoing and any further liability cannot be reliably estimated, a contingent liability exists in respect of any potential additional VAT exposures. No provision has been made in the financial statements.

12.	ULTIMATE PARENT AND CONTROLLING PARTY

The company's parent company is Standard BioTools Europe BV, a company incorporated in the Netherlands which owns 100% of Standard BioTools UK Limited.

The ultimate parent company is Standard BioTools Inc, a company incorporated in America. They are the largest entity preparing group financial statements which includes the net assets of the Company and are publicly available. Their registered address is 2 Tower Place, Suite 2000 South San Francisco, CA 94080.

13.	SHARE BASED PAYMENTS

At the year end the company has restricted stock units with its employees. The equity offered is that of the ultimate parent company Standard BioTools Inc. The awards generally vest over a period of three to four years from the date of issuance. The awards have been valued based on the Black Scholes model.

Under the plan, the term of the options is a maximum of 10 years.

The following table summarises the equity settled share options with employees in the period:

Item

Number

Outstanding at the beginning of the period

84,404

Granted during the year

158,989

Forfeited/cancelled during the period

(31,880

)

Exercised during the period

(59,598

)

Expired during the period

0

Outstanding at the end of the period

151,915

An expense of £110,025 (2023: £25,571) has been recognised as a staff cost; being the fair value of the awards expected to vest, time apportioned over the vesting period.

The vesting expense is recognised on a reasonable allocation of the group expense.